Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Ferring signs telemedicine collaboration with Danish hospital

Will work with North Zealand University Hospital on IBD patient care

Ferring Pharmaceuticals headquarters 

Ferring Pharmaceuticals has signed a telemedicine deal with a Copenhagen hospital that it hopes will transform patient care in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

The Swiss firm will collaborate with North Zealand University Hospital in a multi-year partnership that will be fully funded by Ferring but governed by the hospital.

Ferring's executive VP and chief scientific officer Per Falk said: “Ferring and North Zealand University Hospital both fully embrace the concept of eHealth and its positive effects in relation to patient empowerment.

“This partnership will assure continued focus on eHealth and generate personalised treatment for IBD patients.”

Details of the work are fairly sparse at this stage, with Ferring saying only that it will be using “an innovative eHealth platform” that allows patients to self-monitor and self-treat.

And a company spokesperson told PMLiVE:"This platform and the way it will be used are still under work and that the next step in the roll-out of this initiative will be on August 30 - when a symposium will be held in Copenhagen focusing on the microbiome and eHealth."

It will do this by enabling them to “screen for disease activity, act proactively on their symptoms and increase adherence to therapy”, the pharma firm said in a statement.

North Zealand University Hospital's Professor Pia Munkholm said: “In my clinical practice, IBD patients who are monitored by an e-health programme have a reduced time-to-remission. 

“This effect is linked to the patient's ability to more tightly monitor their condition on the web than in a standard care setting, giving users of the eHealth programme the opportunity to detect a relapse sooner.”

The partners' eHealth work will also focus on evaluating the role of the microbiome - the genes within a person's microbes - in the way patients respond to different treatments.

24th May 2016

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics